Stellar International

Stellar International (formerly Stellar Pharmaceuticals) was a Canadian specialty pharmaceutical company focused on the development and commercialization of polysaccharide-based therapeutic products for the treatment of painful bladder syndrome (interstitial cystitis) and osteoarthritis. The company's flagship products included Uracyst, a sodium chondroitin sulfate solution, and NeoVisc, a sodium hyaluronate injection. Stellar also maintained a portfolio of licensed products, such as Bezalip SR for hyperlipidemia. The company was publicly traded on the TSX Venture Exchange and the OTCBB before rebranding as Tribute Pharmaceuticals in 2011 and subsequently being integrated into Aralez Pharmaceuticals.